SCHEMBL4056623

SCHEMBL4056623

NC(=O)[C](CO)Cc1c[nH]c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ MEN1 O00255 5/20 0.60
▸ KMT2A Q03164 5/20 0.60
▸ ALDH1A1 P00352 4/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ HPGD P15428 1/20 0.60
▸ LMNA P02545 3/20 0.57
▸ SLC6A2 P23975 1/20 0.57
▸ FNTA P49354 1/20 0.57
▸ FNTB P49356 1/20 0.57
▸ PKM P14618 1/20 0.55
▸ MPO P05164 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ PMP22 Q01453 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ CYP3A4 P08684 3/20 0.51
▸ AHR P35869 1/20 0.51
▸ GPR84 Q9NQS5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5717728 0.84 MAPT (0.73) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL40822 0.83 MAPT (0.68) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3262116 0.83 MAPT (0.68) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29376364 0.83 MAPT (0.68) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4631680 0.83 MAPT (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL4598405 0.82 MAPT (0.66) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL15281778 0.82 MAPT (0.66) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL30295582 0.82 MAPT (0.66) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL11122486 0.81 MAPT (0.60) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6245320 0.81 MAPT (0.60) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069328-A1 ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2009-03-12 — — US claimed
EP-2025669-A1 Alpha-alkyl substituted N-acyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2009-02-18 — — EP claimed
US-20090069328-A1 ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2009-03-12 — — US disclosed
EP-2025669-A1 Alpha-alkyl substituted N-acyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2009-02-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069328-A1 ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS FSHR, GNRHR, TPH1 MAPT 4259/4885MEN1 260/4885KMT2A 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback